Patients treated for schizophrenia or bipolar I disorder under the ACCESS model have low levels of service disengagement, high levels of medication adherence and improvements in clinical outcomes, researchers report.
Daniel Schöttle (University Medical Center Hamburg-Eppendorf, Germany) and colleagues explain that ACCESS “was created to offer assertive community treatment embedded in an integrated care program to patients with schizophrenia spectrum disorders.”
Following positive results in an initial 12-month comparative trial (ACCESS I), the ACCESS model was implemented into routine care and extended to patients with bipolar I disorder with psychotic features.
The current ACCESS II Study assessed the efficacy of the model in a new sample of patients over 24 months to test whether treatment effects can be sustained over longer periods under “real-life” conditions.
READ FULL ARTICLE From Medwirenews